What is the 13F Pro Quality Score for RVP?

13F Pro ranks RETRACTABLE TECHNOLOGIES INC (RVP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RVP's current score at https://13fpro.ai/research/RVP (free sign-up required for the full ranking).

Where does 13F Pro source RVP data?

All RETRACTABLE TECHNOLOGIES INC fundamentals and ownership data come directly from SEC EDGAR. RETRACTABLE TECHNOLOGIES INC files with the SEC under CIK 946563. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RVP in?

RETRACTABLE TECHNOLOGIES INC (RVP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RVP research updated on 13F Pro?

RVP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RETRACTABLE TECHNOLOGIES INC(RVP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 946563 RVP stock profile & AI dashboard →

13F Pro Quality Score

22.2/100

Rank #2,646 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

28.6/100

Profitability

12.6/100

Balance Sheet

17.3/100

Earnings Quality

30.0/100

Free Cash Flow

13.1/100

Institutional Flow

36.2/100

Revenue Scale

8.6/100

Dilution Risk

94.9/100

RVP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RETRACTABLE TECHNOLOGIES INC (RVP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RVP at 22.2/100 on a 32-signal composite quality model, placing it at rank #2,646 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (8.6) and profitability (12.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), RETRACTABLE TECHNOLOGIES INC reports quarterly revenue of $7.2M, net income of $-4.2M, free cash flow of $-1.4M. Top institutional holders of RVP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Eversept Partners,, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. RVP trades on the NYSE exchange and files with the SEC under CIK 946563. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RETRACTABLE TECHNOLOGIES INC directly from SEC EDGAR. RETRACTABLE TECHNOLOGIES INC's 13F Pro composite quality score has ranged between 12 and 69 since 2021, currently 22.2 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about RETRACTABLE TECHNOLOGIES INC

Quirks, history, and lore behind RVP — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on the NYSE · headquartered in Texas.
2
The Numbers
Annual revenue in the range of $150–200 million, serving hospitals and clinics that collectively use billions of syringes every year.
3
The History
Founded in the late 1990s, the company was born out of a desire to solve one of healthcare's most persistent and preventable problems: accidental needlestick injuries.
4
The Secret
Its core innovation is a syringe with a built-in retraction mechanism — after injection, the needle automatically snaps back into the barrel, protecting healthcare workers from a potentially deadly poke.
5
The Lore
The founder spent years in a legal battle with larger competitors and distributors, accusing them of anti-competitive practices that kept his safer needle off the market — a David vs. Goliath story that became industry legend.
6
The Giveaway
Its flagship product is the VanishPoint® syringe — the needle disappears on command — made by a company whose very name describes exactly what happens when you're done with the shot.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$7.2M

Net Income

Q1 2026

$-4.2M

Free Cash Flow

Q1 2026

$-1.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+15.8% YoY

$38.3MFY 2025

FY21 $188.4MFY23 $43.6MFY24 $33.0MFY25 $38.3M

Net Income

-5.7% YoY

$-12.6MFY 2025

FY21 $56.1MFY23 $-7.0MFY24 $-11.9MFY25 $-12.6M

Operating Income

-0.3% YoY

$-21.2MFY 2025

FY21 $72.6MFY23 $-11.5MFY24 $-21.1MFY25 $-21.2M

EPS (Diluted)

-7.5% YoY

$-0.43FY 2025

FY21 $1.63FY23 $-0.24FY24 $-0.40FY25 $-0.43

Total Assets

-11.3% YoY

$142.6MFY 2025

FY21 $206.3MFY23 $179.7MFY24 $160.7MFY25 $142.6M

Total Debt

-42.8% YoY

$895.6KFY 2025

FY21 $2.4MFY23 $1.8MFY24 $1.6MFY25 $895.6K

Op. Cash Flow

+38.9% YoY

$-7.1MFY 2025

FY21 $32.8MFY23 $2.8MFY24 $-11.6MFY25 $-7.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$38.3M +15.8%	$33.0M -24.2%	$43.6M -76.9%	$188.4M +130.1%	$81.9M +146.0%	$33.3M
Net Income	$-12.6M -5.7%	$-11.9M -69.5%	$-7.0M -112.5%	$56.1M +131.5%	$24.2M +1907.8%	$-1.3M
Operating Income	$-21.2M -0.3%	$-21.1M -83.7%	$-11.5M -115.8%	$72.6M +201.6%	$24.1M +1910.5%	$-1.3M
EPS (Diluted)	$-0.43 -7.5%	$-0.40 -66.7%	$-0.24 -114.7%	$1.63 +103.7%	$0.80 +1433.3%	$-0.06
Total Assets	$142.6M -11.3%	$160.7M -10.5%	$179.7M -12.9%	$206.3M +96.5%	$105.0M +184.0%	$37.0M
Total Debt	$895.6K -42.8%	$1.6M -15.0%	$1.8M -23.0%	$2.4M -49.9%	$4.8M +38.2%	$3.5M
Operating Cash Flow	$-7.1M +38.9%	$-11.6M -517.7%	$2.8M -91.6%	$32.8M +72.6%	$19.0M +1689.1%	$-1.2M

AI Insight: RVP Financial Trends

RVP faces persistent operating losses and shrinking revenue with no path to profitability visible in latest eight quarters.

• Revenue collapsed from $10M (Q3 2025, Q2 2025) to $7M (Q1 2026), down 30% in two quarters.

• Operating income remains deeply negative across all periods, ranging from -$4M to -$8M per quarter with no improvement trend.

• Equity eroded from $85M (Q2 2024) to $70M (Q1 2026), a 18% decline driven by cumulative losses.

⚠ Operating cash flow has been negative every quarter except Q4 2024 (-$1M), signaling cash burn and sustainability risk.

⚠ Net income swung wildly from -$14M to +$4M, indicating unstable underlying operations and accounting volatility.

AI Insight: RVP Ratio Trends

RVP remains deeply unprofitable with operating margins collapsing to -85.9% in Q1 2026, erasing modest Q3 2025 recovery.

• Operating margin deteriorated from -36.2% in Q3 2025 to -85.9% in Q1 2026, reversing three-quarter improvement trend.

• ROIC worsened to -35.2% in Q1 2026 from -18.8% in Q3 2025; negative across entire 2-year span.

• Net profit margin swung to -58.9% in Q1 2026 from +3.7% in Q3 2025, indicating severe profitability collapse.

⚠ Q4 2025 and Q1 2026 margins suggest structural headwinds; no sustained profitable quarter since Q3 2025.

⚠ Leverage remains minimal (D/E ~0.01), preserving balance sheet flexibility amid operational deterioration.

Get alerted when RVP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RETRACTABLE TECHNOLOGIES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RVP

VANGUARD CAPITAL MANAGEMENT LLC
$385.1K581,736 sh
Eversept Partners, LP
$384.3K580,919 sh
RENAISSANCE TECHNOLOGIES LLC
$267.3K404,007 sh
BlackRock, Inc.
$159.5K241,122 sh
GEODE CAPITAL MANAGEMENT, LLC
$98.9K149,448 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$58.6K88,543 sh
VANGUARD FIDUCIARY TRUST CO
$56.4K85,260 sh
STATE STREET CORP
$39.6K59,796 sh
WealthTrust Axiom LLC
$34.9K52,833 sh
LPL Financial LLC
$33.5K50,566 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$385.1K	581,736
Eversept Partners, LP	$384.3K	580,919
RENAISSANCE TECHNOLOGIES LLC	$267.3K	404,007
BlackRock, Inc.	$159.5K	241,122
GEODE CAPITAL MANAGEMENT, LLC	$98.9K	149,448
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$58.6K	88,543
VANGUARD FIDUCIARY TRUST CO	$56.4K	85,260
STATE STREET CORP	$39.6K	59,796
WealthTrust Axiom LLC	$34.9K	52,833
LPL Financial LLC	$33.5K	50,566

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RVP on your watchlist

Track score changes the day RETRACTABLE TECHNOLOGIES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RVP a good stock to buy?

13F Pro's AI-powered analysis of RETRACTABLE TECHNOLOGIES INC (RVP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RVP are available on the RVP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RVP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RVP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RETRACTABLE TECHNOLOGIES INC's investment landscape.